证券简称：安必平 证券代码：688393 广州安必平医药科技股份有限公司 投资者关系活动记录表 （2022 年 6 月） | --- | --- | --- | |-------------------------|---------------------------------------------------------------------------------------------|---------------------------------------------------------------------| | 投资者关系 \n活动类别 | □特定对象调研 □分析师会议 \n□媒体采访 □业绩说明会 \n□新闻发布会 □路演活动 \n□现场参观 √其他 | | | | 参与单位名称 九泰基金、成都海天鸿 | | | 时间 2022 | 年 6 月 22 日、 6 | 月 24 日 | | 地点 线上会议 | | | | | 董事会秘书：蔡幸伦 | | | 公司接待人员 | 投资者关系高级经理：陈元元 证券事务代表：杜坤 | | | | 交流的主要问题及答复： | | | | 1 ...

2022 年第三季度报告 证券代码：688393 证券简称：安必平 1 / 18 广州安必平医药科技股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比 | 年初至报告期末 | 年初至报告期 | | --- | --- | --- | --- | --- | | | | 上年同期增 | | 末比上年同期 | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 131,800,363.60 | 14.90 | 374 ...

Financial Performance - The company reported a total revenue of 100 million CNY for the first half of 2022, representing a year-on-year increase of 15%[11] - The company achieved operating revenue of CNY 242.53 million, a 14.20% increase compared to the same period last year[17] - The company reported a total revenue of RMB 15.3 billion for the first half of 2022, with a net profit of RMB 3.13 billion, representing a year-on-year increase of 12.6%[60] - Net profit attributable to shareholders decreased by 30.81% to CNY 35.21 million, while the net profit excluding non-recurring gains and losses fell by 28.37% to CNY 31.71 million[17] - The net cash flow from operating activities declined by 49.69% to CNY 11.94 million, primarily due to changes in product sales structure and increased sales costs[17] Research and Development - Research and development expenses increased by 30% in the first half of 2022, reflecting the company's commitment to innovation and new technology development[11] - R&D expenditure accounted for 12.90% of operating revenue, an increase of 5.73 percentage points compared to the previous year[17] - The company reported a total R&D expenditure of ¥31,276,582.98, representing a 105.50% increase compared to ¥15,219,824.64 in the previous year[55] - The number of R&D personnel increased to 163, accounting for 20.90% of the total workforce, compared to 20.17% in the same period last year[63] - The company has developed over 580 registered/recorded products related to pathological diagnosis, making it one of the most comprehensive platforms in the domestic tumor screening and diagnosis industry[23] Product Development and Innovation - The company plans to launch two new diagnostic products in Q4 2022, aiming to capture a 10% market share in the new segments[11] - The company launched a series of digital pathology products, integrating cutting-edge technologies such as the internet and big data to enhance diagnostic capabilities[26] - The company has developed an automated sedimentation-based liquid-based cytology system, enhancing diagnostic efficiency and reducing contamination risks[42] - The company has successfully developed an AI-assisted diagnostic product for cervical cytology in collaboration with Tencent, which has received positive feedback in clinical research evaluations[43] - The company has established a comprehensive cervical cancer screening solution, integrating cytology and HPV testing, which has been well-received by clinical practitioners[66] Market Strategy and Expansion - Future outlook includes a projected revenue growth of 25% for the full year 2022, driven by new product launches and market expansion strategies[11] - The company is exploring potential acquisitions to enhance its technology capabilities and expand its market presence in the Asia-Pacific region[11] - The company aims to expand its market presence by developing cost-effective cervical cancer screening solutions for grassroots healthcare institutions[66] - The company has established a marketing network covering 31 provinces, serving nearly 2,000 medical institutions, including over 1,000 tertiary hospitals and more than 700 top-tier hospitals[71] - The company is actively participating in the construction of pathology departments in grassroots medical institutions, promoting the integration of pathology services[27] Financial Management - The company maintains a strong cash position with cash and cash equivalents totaling 50 million CNY as of June 30, 2022[11] - Cash and cash equivalents at the end of the period reached ¥254,402,776.88, representing 18.75% of total assets, an increase of 16.87% compared to the previous year[114] - The company’s investment cash flow turned positive at 46.98 million RMB, a significant improvement from a negative 99.87 million RMB in the previous period[112] - The company’s management expenses surged by 98.73% to 33.63 million RMB, driven by salary adjustments and increased personnel costs[112] - The company’s total liabilities decreased, with accounts payable down by 14.68% to ¥42,455,874.16, indicating improved cash flow management[116] Risk Management - The company has identified key risks including regulatory changes and market competition, which could impact future performance[11] - The company faces risks related to single product reliance, market competition, and potential price declines in its core LBP and PCR product lines, which account for over 50% of revenue[105] - The company has established measures to resolve related party transactions involving the controlling shareholder[138] - The company has a strategy in place to address competition among peers, ensuring compliance with regulations[138] - The company will comply with all relevant laws and regulations regarding share reduction and will announce any reductions in accordance with legal requirements[143] Corporate Governance - The company appointed a new CFO, Hou Quanneng, on May 16, 2022, following the departure of the previous CFO, Yang Zhiliang[126] - The company held its annual general meeting on April 22, 2022, where all resolutions were passed without any objections[123] - The company has implemented a restricted stock incentive plan, approved by the board on April 1, 2022, with details disclosed on April 2, 2022[127] - The controlling shareholder, Cai Xiangting, committed to not transferring or entrusting the management of shares held before the IPO for 36 months from the date of listing[138] - The company has committed to maintaining transparency and accuracy in its financial disclosures to protect investor interests[183] Environmental Responsibility - The company has been recognized as a "Green+" enterprise for its commitment to environmental protection and energy conservation[131] - The company has taken measures to reduce carbon emissions by improving production processes and energy efficiency[132] - The company is not classified as a key pollutant discharge unit and has obtained necessary environmental permits[130] - The company ensures the independence of its subsidiaries to avoid unnecessary related-party transactions, maintaining fair pricing in any unavoidable transactions[200] - The company has established measures to prevent dilution of immediate returns from fundraising activities[175]

Financial Performance - The company's operating revenue for Q1 2022 was CNY 120,089,759.96, representing a year-on-year increase of 20.68%[5] - The net profit attributable to shareholders decreased by 26.40% to CNY 19,624,115.78 compared to the same period last year[5] - Basic and diluted earnings per share were both CNY 0.21, down 27.59% from the same period last year[6] - In Q1 2022, the company's net profit was CNY 17,321,842.35, a decrease of 34% compared to CNY 26,233,758.61 in Q1 2021[19] - The company reported a total profit of CNY 20,986,803.66, down 33% from CNY 31,255,584.08 in the previous year[19] - The total comprehensive income for the period was CNY 17,321,842.35, reflecting a decrease from CNY 26,233,758.61 in the previous year[20] Research and Development - Research and development expenses totaled CNY 14,813,078.40, which is an increase of 143.97% year-on-year, accounting for 12.34% of operating revenue[6] - Research and development expenses increased significantly to CNY 14,813,078.40, compared to CNY 6,071,613.10 in Q1 2021, marking a 144% rise[19] - Research and development expenses increased significantly to CNY 11,278,702.55, up 180.5% from CNY 4,024,853.55 in the same period last year[30] Cash Flow and Liquidity - The net cash flow from operating activities was CNY 142,227.31, reflecting a significant decrease of 90.91% compared to the previous year[6] - The cash flow from operating activities showed a net increase of CNY 142,227.31, a decline from CNY 1,564,154.14 in Q1 2021[23] - The company's cash and cash equivalents at the end of the period totaled CNY 310,322,384.54, down from CNY 662,991,698.93 at the end of Q1 2021[24] - The net cash flow from operating activities in Q1 2022 was -¥3,572,285.51, compared to a positive net cash flow of ¥426,769.10 in Q1 2021, indicating a significant decline[33] - The company's cash and cash equivalents at the end of Q1 2022 stood at ¥290,606,781.98, compared to ¥644,469,476.43 at the end of Q1 2021, reflecting a decrease of approximately 55.1%[35] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,374,585,523.28, a slight increase of 0.65% from the end of the previous year[6] - Total assets as of March 31, 2022, were RMB 1,374,585,523.28, slightly up from RMB 1,365,683,854.03 at the end of 2021[16] - Total liabilities decreased to RMB 146,288,394.23 from RMB 155,959,139.08 at the end of 2021, a reduction of 6.5%[17] - The total liabilities increased to CNY 188,998,204.29 from CNY 183,613,066.30 at the end of 2021[28] - The company's equity attributable to shareholders increased to RMB 1,223,626,796.20 from RMB 1,204,002,680.42, reflecting a growth of 1.6%[17] Shareholder Information - The total number of common shareholders at the end of the reporting period was 7,394[9] - The largest shareholder, Cai Xiangting, holds 21.23% of the shares, totaling 19,817,000 shares[10] Market and Strategic Developments - The company has not disclosed any new product developments or market expansion strategies in the current report[13] - There are no significant mergers or acquisitions reported during the quarter[13] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[30]

Financial Performance - The company's operating revenue for 2021 was approximately ¥438.99 million, representing a year-over-year increase of 16.93% compared to ¥375.43 million in 2020[22]. - The net profit attributable to shareholders for 2021 was approximately ¥79.78 million, a decrease of 5.86% from ¥84.75 million in 2020[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥62.78 million, down 11.28% from ¥70.76 million in 2020[22]. - The net cash flow from operating activities for 2021 was approximately ¥59.61 million, a decline of 34.79% compared to ¥91.43 million in 2020[22]. - The comprehensive gross profit margin for 2021 was 77.92%, a decrease of 1.85 percentage points compared to 2020, primarily due to an increase in the proportion of purchased products[126]. - Revenue from external diagnostic products was 437.44 million yuan, with a gross profit margin of 77.94%, reflecting a year-on-year increase of 16.79%[128]. - Service revenue saw a significant increase of 255.34%, reaching 16.78 million yuan, indicating successful expansion in service offerings[128]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of 2.70 CNY per 10 shares, totaling approximately 25,201,800 CNY, which represents 31.59% of the net profit attributable to shareholders for 2021[6]. - The company’s profit distribution plan has been approved by the board and is pending approval from the shareholders' meeting[6]. Audit and Compliance - The company has received a standard unqualified audit report from Zhonghui Certified Public Accountants[5]. - The company has detailed potential risks in its annual report, which can be found in the section discussing operational conditions and risk factors[4]. - There are no non-operating fund occupations by controlling shareholders or related parties[8]. - The company has not violated decision-making procedures for providing guarantees[9]. - The company has not reported any special arrangements for corporate governance[9]. Research and Development - R&D investment reached 45.90 million yuan, up 65.52% year-on-year, accounting for 10.46% of operating revenue[33]. - The total R&D investment for the year was approximately ¥45.90 million, representing a 65.52% increase compared to the previous year's ¥27.73 million[87]. - The company has established a dedicated R&D team of 148 people, accounting for 21.23% of total employees, and has participated in multiple national and provincial research projects to enhance its technological innovation capabilities[102]. - The company is focusing on enhancing R&D efforts in tumor screening and diagnosis across multiple technology platforms[88]. Market and Product Development - The company has developed a comprehensive solution for cervical cancer screening, integrating cytology and HPV molecular testing, which significantly improves specimen satisfaction and detection rates compared to traditional methods[97]. - The company is actively developing a cervical cytology AI-assisted diagnostic product in collaboration with Tencent, aiming to establish industry standards for cervical liquid-based cytology databases[66]. - The company is focusing on the development of automated, standardized, digitalized, and intelligent pathology departments, integrating cutting-edge technologies such as big data and cloud computing[66]. - The company has developed 570 registered/recorded pathology diagnosis-related products, making it one of the most comprehensive technology platforms in the domestic tumor screening and diagnosis industry[63]. Strategic Partnerships and Collaborations - The company has established a strategic partnership with Tencent AILab to develop AI-assisted diagnostic products for cervical cytology[31]. - The company is exploring collaborative models to enhance pathology services in grassroots hospitals, addressing the uneven distribution of pathology resources in China[75]. - The company has established partnerships with leading pathology experts to enhance its research capabilities and project execution[102]. Risks and Challenges - The company faces risks related to new product development and registration, which are critical for maintaining its market position[111]. - The company anticipates increased market competition and potential price declines for its cervical cancer screening products due to industry maturation[114]. - The company faces risks related to accounts receivable collection due to rapid growth in sales, with accounts receivable aging typically within one year[118]. Governance and Management - The company has maintained a stable leadership structure, with all directors and key technical personnel holding their positions since their appointment dates[181]. - The company has a diverse management team with extensive experience in various sectors, ensuring a robust governance structure[183]. - The board of directors attended 10 meetings in total, with all members present at each meeting[195]. Investment and Acquisitions - The company made significant equity investments in 2021, including 100% ownership in multiple subsidiaries focused on sales and medical diagnostics[154]. - The company is actively expanding its market presence through strategic investments in diagnostic and medical service companies[155]. - The company has established multiple investment partnerships, with ownership stakes ranging from 9.09% to 100% in various entities[154]. Sales and Marketing - The company has established a nationwide marketing network with over 1,900 clients, including 976 tier-three hospitals[169]. - The company is focusing on developing distribution channels, resulting in a faster growth rate in distribution sales compared to direct sales[132]. - The company’s marketing strategy emphasizes a "direct sales as primary, distribution as supplementary" model, enhancing customer engagement through training and technical support[37].

一、 主要财务数据 2021 年第三季度报告 证券代码：688393 证券简称：安必平 广州安必平医药科技股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 注:"本报告期"指本季度初至本季度末 3 个月期间，下同。 (二)非经常性损益项目和金额 (一)主要会计数据和财务指标 单位：元 币种：人民币 单位：元 币种：人民币 | 项目 | 本报告期金额 | 年初至报告期末金额 | 说明 | | --- | --- | --- | --- | | 非流动性资产处置损 益（包括已计提资产减 | -48,729.55 | 311,449.16 | | | 值准备的冲销部分） 计入当期 ...

Financial Performance - The company reported a total revenue of 500 million CNY for the first half of 2021, representing a 20% increase compared to the same period last year[12]. - The company's operating revenue for the first half of 2021 was CNY 212,376,439.30, representing a 46.65% increase compared to CNY 144,820,362.67 in the same period last year[18]. - The net profit attributable to shareholders was CNY 50,880,437.99, a 56.09% increase from CNY 32,596,311.84 year-on-year[18]. - The company reported a total revenue of 129,561,215.0 RMB for the first half of 2021, with a net profit of 15,219,824.6 RMB, representing a significant increase compared to the previous period[44]. - The company achieved operating revenue of CNY 212.38 million in the first half of 2021, representing a year-on-year growth of 46.65%[72]. - Net profit attributable to shareholders reached 50.88 million yuan, up 56.09% year-on-year[72]. - The net profit after deducting non-recurring gains and losses was 44.26 million yuan, an increase of 41.99% compared to the previous year[72]. Research and Development - The company is investing 30 million CNY in R&D for new technologies aimed at enhancing diagnostic accuracy and efficiency[12]. - The research and development expenditure accounted for 7.17% of operating revenue, a decrease of 0.61 percentage points from the previous year[20]. - The company achieved a total R&D investment of ¥15,219,824.64, representing a 35.11% increase compared to ¥11,264,515.31 in the previous period[39]. - Research and development expenses totaled CNY 15.22 million, reflecting a 35.11% increase year-on-year, accounting for 7.17% of operating revenue[61]. - The company has developed a new reagent consumable for the LBP-5548 fully automatic immunohistochemistry staining machine, improving reagent usage efficiency[36]. - The company is developing AI-assisted diagnostic products, including a cervical pathology diagnosis system, which is currently under registration for medical device certification[43]. - The company has established three major technology platforms: cytological diagnosis, molecular diagnosis, and immunodiagnosis, covering various clinical diagnostic needs[29]. Market Expansion and Strategy - The company has provided a performance guidance for the second half of 2021, expecting a revenue growth of 25% year-over-year[12]. - Market expansion plans include entering two new provinces, targeting a 10% market share within the first year of operation[12]. - The company aims to expand its market presence through the development of innovative diagnostic technologies and strategic partnerships[47]. - The company has established partnerships with two grassroots medical institutions to co-build pathology departments, aiming to enhance the service capabilities of county-level hospitals[65]. - The company is focusing on expanding its marketing network to grassroots hospitals and third-party testing institutions, with new subsidiaries established in Chongqing, Anhui, and Hunan[63]. Product Development and Innovation - New product launches include a state-of-the-art diagnostic kit, projected to contribute an additional 50 million CNY in revenue by year-end[12]. - The company has developed over 500 products covering various cancer types, including cervical cancer, breast cancer, and lung cancer, utilizing core technologies such as LBP, PCR, FISH, and IHC[50]. - The company’s products are designed to meet the needs of different levels of medical institutions, ensuring a comprehensive product line[29]. - The company has successfully integrated its self-developed instruments with its reagents, achieving automated batch processing and stable quality[30]. - The company has launched three major brands for its automated staining equipment, achieving comprehensive coverage of different customer needs[34]. Financial Position and Assets - The company's total assets increased by 0.69% to CNY 1,301,105,278.68 compared to CNY 1,292,250,751.64 at the end of the previous year[19]. - As of the end of the reporting period, the company's total assets amounted to CNY 1,301.11 million, with net assets attributable to shareholders of CNY 1,172.67 million, indicating a solid financial position[60]. - The company reported a total current asset of CNY 994,316,320.55, down from CNY 1,028,196,554.47, a decrease of about 3.3%[138]. - The company’s cash and cash equivalents decreased to CNY 494,107,999.88 from CNY 622,544,392.72, a decline of approximately 20.6%[137]. - The company’s total liabilities reached CNY 134,536,250.63, compared to CNY 124,667,352.15, marking an increase of around 7.0%[134]. Risks and Challenges - The company has identified potential risks including regulatory changes and market competition, which are detailed in the risk factors section of the report[4]. - The company faces risks related to increased market competition and potential price declines for its cervical cancer screening products due to intensified competition and policy implementations[68]. - The company is facing risks related to customer diversification and sales model differences compared to industry peers[69]. Shareholder and Governance - The board confirmed that there are no non-operational fund occupations by controlling shareholders or related parties[4]. - The company has implemented an equity incentive plan to align the interests of shareholders, the company, and core team members, enhancing motivation and creativity[61]. - The controlling shareholder and actual controller, Cai Xiangting, committed to not transferring or entrusting the management of shares for 36 months from the date of the company's stock listing[96]. - The company ensures that any share reduction will be conducted in compliance with the regulations set by the China Securities Regulatory Commission and the Shanghai Stock Exchange[98]. Compliance and Legal Matters - The company has not reported any significant litigation or arbitration matters during the reporting period[107]. - The company has not disclosed any temporary announcements related to significant transactions[110]. - The company has not reported any violations or penalties involving its directors, supervisors, or senior management[107].

Financial Performance - Operating revenue surged by 158.72% to CNY 99,508,003.08 year-on-year[7] - Net profit attributable to shareholders increased by 169.87% to CNY 26,664,570.54 compared to the same period last year[7] - Basic earnings per share rose by 107.14% to CNY 0.29[7] - The company's operating revenue for Q1 2021 reached ¥99,508,003.08, representing a 158.72% increase compared to ¥38,461,902.33 in Q1 2020, primarily due to a significant increase in sales volume[14] - Net profit for Q1 2021 was ¥26,233,758.61, representing a 189.5% increase from ¥9,064,366.31 in Q1 2020[29] - Net profit for Q1 2021 was ¥21,729,658.91, representing a 143.5% increase from ¥8,942,163.07 in Q1 2020[32] Cash Flow - Net cash flow from operating activities improved significantly to CNY 1,564,154.14, compared to a negative CNY 2,207,715.69 in the previous year[7] - The net cash flow from operating activities improved to ¥1,564,154.14, a significant recovery from a negative cash flow of -¥2,207,715.69 in Q1 2020, driven by increased sales collections and government subsidies[14] - The company recorded a net increase in cash and cash equivalents of ¥27,720,827.30 in Q1 2021, contrasting with a decrease of ¥22,129,118.89 in Q1 2020[36] - The company reported a cash flow from operating activities of ¥1,564,154.14, a turnaround from a negative cash flow of ¥2,207,715.69 in Q1 2020[36] Assets and Liabilities - Total assets increased by 1.94% to CNY 1,317,292,767.74 compared to the end of the previous year[7] - The company's total assets amounted to 1,317.29 million CNY, an increase from 1,292.25 million CNY at the end of 2020[22] - The company's total current assets reached 1,073.81 million CNY, compared to 1,062.92 million CNY at the end of 2020, reflecting a growth of approximately 1.7%[20] - The company's total liabilities decreased by 60.90% in employee compensation payable, dropping to ¥5,496,480.43 from ¥14,058,838.44, reflecting the impact of year-end bonus provisions from the previous year[13] - Total liabilities increased to ¥141,989,765.76 from ¥139,333,798.27, a rise of 1.2%[26] Shareholder Information - The total number of shareholders reached 7,956 by the end of the reporting period[10] - The largest shareholder, Cai Xiangting, holds 21.23% of the shares, totaling 19,817,000 shares[10] Research and Development - R&D expenditure as a percentage of operating income decreased by 4.95 percentage points to 6.10%[7] - Research and development expenses increased by 42.81% to ¥6,071,613.10 from ¥4,251,649.33, indicating a focus on enhancing product development[14] - Research and development expenses for Q1 2021 were ¥6,071,613.10, compared to ¥4,251,649.33 in Q1 2020, an increase of 43.0%[28] Tax and Other Expenses - The company’s tax expenses rose by 202.02% to ¥5,021,825.47 from ¥1,662,723.83, reflecting increased profitability[14] - Sales expenses increased to ¥31,769,298.09 in Q1 2021, compared to ¥8,376,673.96 in Q1 2020, reflecting expanded marketing efforts[32] Incentive Plans - The company approved a restricted stock incentive plan to grant 2.00 million shares, representing 2.14% of the total share capital, with an initial grant of 1.70 million shares (1.82% of total share capital) and a reserve of 0.30 million shares (0.32% of total share capital) [15] - The first grant date for the restricted stock was set for February 8, 2021, with a grant price of 31.00 CNY per share for 170.30 thousand shares to 129 incentive recipients [16]

Financial Performance - The company's operating revenue for 2020 was CNY 375,433,111.72, representing a year-over-year increase of 5.71% compared to CNY 355,159,969.62 in 2019[21]. - Net profit attributable to shareholders for 2020 was CNY 84,745,713.59, reflecting a 14.54% increase from CNY 73,988,897.22 in 2019[21]. - The company's total assets at the end of 2020 reached CNY 1,292,250,751.64, a significant increase of 140.21% from CNY 537,961,728.25 in 2019[21]. - Basic earnings per share for 2020 were CNY 1.09, up 2.83% from CNY 1.06 in 2019[22]. - The company's total profit reached CNY 99,853,025.37, an increase of 14.45% compared to the previous year[107]. - The operating cost increased to CNY 75,964,151.22, reflecting a significant rise of 31.10% from the previous year[109]. - The company's comprehensive gross profit margin for 2020 was 79.77%, a decrease of 3.92 percentage points compared to 2019[111]. - The revenue from self-produced products was CNY 336,619,815.39, with a gross margin of 83.92%, down by 2.81 percentage points year-on-year[112]. - The revenue from purchased products was CNY 33,226,096.32, with a gross margin of 39.50%, decreasing by 7.64 percentage points compared to the previous year[112]. Research and Development - The company's R&D expenditure as a percentage of operating revenue increased to 7.39% in 2020 from 6.15% in 2019, indicating a focus on innovation[22]. - The company achieved a total R&D investment of ¥27,732,236.90, representing a 26.87% increase compared to the previous year[58]. - R&D investment accounted for 7.39% of total operating revenue, up from 6.15% in the previous year, indicating a 1.24 percentage point increase[58]. - The company has a high-quality R&D team of over 110 members, accounting for 21.44% of total employees, and has established an effective innovation mechanism to enhance its technological capabilities[72]. - The company is focused on improving the efficiency and quality of work for pathologists through innovative solutions[62]. Product Development and Market Position - The company operates in the high-tech pharmaceutical sector, focusing on medical technology and automation[13]. - The company has established three major technology platforms for in vitro diagnostics, covering cytology, molecular diagnostics, and immunodiagnostics[32]. - The company has developed several core technologies, including sedimentation liquid-based cytology and real-time fluorescence PCR preparation technology, enhancing its product offerings[32]. - The company has developed a PCR reagent kit capable of detecting 18 HPV subtypes simultaneously with high sensitivity and low amplification bias[51]. - The company has launched a series of automated pathology diagnostic instruments, including a fully automated sample processing machine and a fully automated immunohistochemistry staining machine[53]. - The company has developed a comprehensive cervical cancer screening solution that integrates cytological and HPV testing methods, significantly improving specimen satisfaction and detection rates compared to traditional methods[68]. Market Strategy and Expansion - The company aims to become a leading player in the domestic in vitro diagnostic field by focusing on product innovation and expanding its product application range[140]. - The marketing strategy includes building a direct sales network across various levels of medical institutions and expanding into rapidly growing grassroots hospitals and third-party testing institutions[143]. - The company will explore international markets when conditions are favorable to achieve global product reach[143]. - The company has established a marketing network covering nearly 1,800 medical institutions across 31 provinces, with direct sales accounting for over 60% of its sales model[35]. Corporate Governance and Compliance - The company has received a standard unqualified audit report from Zhonghui Certified Public Accountants[5]. - The board of directors has confirmed the authenticity, accuracy, and completeness of the annual report[4]. - The company has not reported any non-operational fund occupation by controlling shareholders or related parties[8]. - The company has not indicated any special arrangements in corporate governance[8]. - The company will ensure that related party transactions are conducted at fair market prices to protect the interests of shareholders[169]. Risks and Challenges - The company has outlined potential risks in its operations, which are detailed in the report[4]. - The company faces risks related to the inability to keep up with industry trends in product development, which could impact future growth potential[92]. - The company is exposed to risks from increased competition in the in vitro diagnostics market, with new entrants and existing competitors enhancing their capabilities[101]. - The company acknowledges the risk of core technology leakage and the potential loss of key technical personnel, which could impact future development capabilities[94]. Dividend Policy - The company plans to distribute a cash dividend of 2.80 RMB per 10 shares, totaling approximately 26,135,200 RMB, which represents 30.84% of the net profit attributable to shareholders for 2020[6]. - The profit distribution plan was approved by the board and supervisory committee, with independent directors expressing clear agreement[151]. - The company has a profit distribution policy that mandates at least 20% of the distributable profit to be allocated for cash dividends if the audited net profit is positive[147]. Financial Position and Assets - The company achieved a total asset of 1,292.25 million yuan and a net asset of 1,167.97 million yuan by the end of the reporting period, indicating a solid financial position[82]. - The company's cash and cash equivalents increased significantly to ¥635,270,871.63, representing 49.16% of total assets, up from 15.93% in the previous period, a growth of 641.29%[129]. - The company's receivables from accounts rose to ¥184,749,414.65, accounting for 14.3% of total assets, an increase of 9.04% compared to the previous period[130]. - The company's fixed assets reached ¥54,496,950.86, representing 4.22% of total assets, with a notable increase attributed to fundraising for R&D investments[130].

Financial Performance - Operating revenue for the first nine months increased by 5.75% year-on-year, amounting to CNY 264,639,058.28[6] - Net profit attributable to shareholders grew by 10.18% year-on-year, reaching CNY 66,376,047.17[6] - Total operating revenue for Q3 2020 reached ¥119,818,695.61, a 27.1% increase from ¥94,348,622.56 in Q3 2019[30] - Net profit for Q3 2020 was ¥33,639,133.69, representing a 17.4% increase compared to ¥28,543,221.50 in Q3 2019[31] - The total profit for Q3 2020 was ¥30,201,030.22, up from ¥26,093,850.01 in Q3 2019, reflecting a growth of 8.1%[35] - The company reported a total comprehensive income for Q3 2020 of ¥33,639,133.69, compared to ¥28,543,221.50 in Q3 2019, indicating a growth of 17.4%[36] Assets and Liabilities - Total assets increased by 130.41% year-on-year, reaching CNY 1,239,495,993.32[6] - The total assets of the company stood at ¥1,239,495,993.32, up from ¥537,961,728.25 year-over-year[24] - Total liabilities decreased to ¥89,882,155.46 from ¥93,334,074.16, reflecting improved financial stability[24] - Total liabilities as of Q3 2020 amounted to ¥119,279,769.51, up from ¥105,597,668.44 in the previous year[28] - Total current liabilities were reported at ¥53,065,135.17, a decrease from ¥57,761,738.81, indicating improved liquidity management[23] Shareholder Information - Net assets attributable to shareholders rose by 159.34% compared to the previous year, totaling CNY 1,149,601,367.46[6] - The total number of shareholders reached 10,537 by the end of the reporting period[12] - The top shareholder, Cai Xiangting, holds 21.23% of the shares, totaling 19,817,000 shares[12] - Shareholders' equity increased significantly to ¥1,149,613,837.86 from ¥444,627,654.09, showcasing strong retained earnings and capital growth[24] Cash Flow - The net cash flow from operating activities decreased by 27.88% year-on-year, totaling CNY 41,442,592.34[6] - Cash flow from financing activities showed a net increase of CNY 648,008,526.05, a significant improvement from a net outflow of CNY -19,219,250.00 in Q2 2020[39] - The cash flow from operating activities for the first three quarters of 2020 was ¥271,986,515.96, slightly down from ¥273,345,531.90 in the same period of 2019[37] Research and Development - R&D expenditure as a percentage of operating income increased by 1.18 percentage points to 6.60%[7] - Research and development expenses for Q3 2020 totaled ¥6,188,761.20, an increase of 16.4% from ¥5,311,490.58 in Q3 2019[30] - Research and development expenses for Q3 2020 were ¥4,513,963.91, an increase of 52.2% from ¥2,964,224.35 in Q3 2019[35] Investment Activities - The company reported a net cash flow from financing activities of ¥648,008,526.05, a significant increase compared to the previous year[16] - The company has invested ¥102,233,595.00 in construction projects, up from ¥81,192,580.35, highlighting ongoing expansion efforts[23] - The company received CNY 649,520,526.05 from investment in Q3 2020, compared to CNY 1,700,000.00 in the previous quarter[39] Market Strategy - The company is focused on expanding its market presence and enhancing product development strategies[18] - The company plans to continue expanding its market presence and invest in new product development[30] Other Financial Metrics - Basic and diluted earnings per share increased by 5.81% to CNY 0.91[7] - The weighted average return on net assets decreased by 1.92 percentage points to 12.53%[7] - Other income increased by 90.34% to ¥1,090,906.00, attributed to government subsidies and VAT refunds[16]